Patient

P2B-092

completed Phase II

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · Stanford University (Stanford, CA) (Dr. Nolan)

consented 2013-03-21

Stanford University (Stanford, CA)

Adverse events

Serious AEs

Open data queries

Luna dropout signal

—

not on Luna

Adverse events 3

mild assessed 2013-05-14

Grade 1 stomatitis with onset in cycle 3 (2013-05-14); assessed as related to study drug (probable); resolved 2013-05-24.

moderate assessed 2013-05-13

Grade 2 decreased appetite with onset in cycle 3 (2013-05-13); assessed as not related to study drug (unlikely); resolved 2013-06-03.

moderate assessed 2013-05-07

Grade 2 alopecia with onset in cycle 2 (2013-05-07); assessed as related to study drug (probable); not resolved at last follow-up.

Data queries 0

No data queries

The CDM sweep raises queries on inconsistent fields.

Luna engagement

This participant doesn't use Luna

Invite them from the site to track mood, adherence and check-ins.

Open Luna users